Fig. 6: APOH expression associates with sorafenib response in patients with liver cancer.
From: Serum apolipoprotein H determines ferroptosis resistance by modulating cellular lipid composition

Expression of SLC7A11 (A), GPX4 (B), APOH (C), and SCD (D) were evaluated in patients with HCC hepatocellular carcinoma, they were categorized as 21 responders and 46 non-responders to sorafenib treatment using the GEO dataset (GSE109211). The statistical difference of the two groups was compared through the t-test. **P < 0.01, ****P < 0.0001.